Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2018-01-17 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
中德证券有限责任公司关于公司2018年度预计日常关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Zhongde Securities regarding the 2018 expected daily related-party transactions of Qidi Guhan Group Co., Ltd. It discusses the nature, approval process, pricing, and risk of related-party transactions, including board and independent director approvals, and the need for shareholder meeting approval. The document is not a financial report like an annual or interim report, nor is it an earnings release or a call transcript. It is a formal verification opinion related to regulatory compliance and approval of related-party transactions, which aligns with the category of Audit Report / Information (AR) as it involves audit opinions and regulatory compliance verification but is not a full annual report. The document length (5611 characters) and content confirm it is a standalone audit/verification report rather than an announcement or a brief notice. Therefore, the best classification is AR (Audit Report / Information). FY 2018
2018-01-17 Chinese
关于2018年度日常关联交易预计公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected daily related-party transactions for the year 2018 by 启迪古汉集团股份有限公司. It details the nature of the transactions, the parties involved, pricing principles, approval processes, and includes opinions from independent directors and the sponsoring institution. The document is relatively short (4301 characters) and serves as a disclosure of anticipated related-party transactions rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis. It is a regulatory announcement about related-party transactions, which fits best under the category of Regulatory Filings (RNS) as it does not match other more specific categories like Annual Report, Interim Report, or Audit Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-01-17 Chinese
第八届监事会临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at a temporary supervisory board meeting of the company. It details the approval of a related-party sales agency agreement and the estimated transaction amount for 2018. It includes voting results and mentions that the matter requires shareholder approval. The document is short (771 characters) and does not contain financial statements or detailed financial data. It is an announcement of a board/management decision rather than a full report or financial filing. Therefore, it fits best under Board/Management Information (MANG).
2018-01-17 Chinese
独立董事对关联交易的事前审核意见
Board/Management Information Classification · 95% confidence The document is a pre-approval opinion from independent directors regarding related party transactions, referencing regulatory guidelines and company governance rules. It is a formal opinion letter rather than a full report or announcement of voting results. The content is focused on governance and compliance with related party transaction rules, which aligns with Board/Management Information filings that announce or document board-level decisions or opinions. The document length is short and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a voting result announcement or a proxy solicitation. Therefore, the best fit is Board/Management Information (MANG).
2018-01-17 Chinese
关于使用部分闲置募集资金购买的理财产品到期赎回并继续购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the company regarding the use of idle raised funds to purchase and redeem financial products, specifically structured deposits. It details the amounts, dates, types of products, risk disclosures, and approvals by the board and shareholders. The document is relatively short (3159 characters) and focuses on the progress and status of the use of raised funds for financial products, not on comprehensive financial statements or detailed financial performance. It does not contain quarterly or annual financial data, nor is it a transcript, audit report, or management discussion. It is an update on capital usage related to fundraising proceeds, which fits the category of Capital/Financing Update (CAP).
2018-01-10 Chinese
2017年度定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2017年度定期现场检查报告" which translates to "2017 Annual Regular On-site Inspection Report". It is issued by a sponsor institution (中德证券有限责任公司) and involves detailed inspection of company governance, internal controls, information disclosure, use of raised funds, and other compliance matters. The content includes checklists, interviews, and verification of company practices and disclosures, typical of a regulatory or audit inspection report rather than a full annual report or financial statement. There is no indication that this is an annual report (10-K), earnings release, or management discussion. It is a standalone inspection report focusing on compliance and internal controls, which fits the definition of an Audit Report / Information (AR). The document length is about 4936 characters, which is substantive and contains detailed findings, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2017
2018-01-05 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.